MEDSURGE MUPIROCIN NASAL OINTMENT mupirocin (as calcium) 20 mg/g (2% w/w) ointment tube Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge mupirocin nasal ointment mupirocin (as calcium) 20 mg/g (2% w/w) ointment tube

medsurge pharma pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - medsurge mupirocin nasal ointment is indicated for the elimination of nasal carriage of staphylococci, including methicillin resistant staphylococcus aureus (mrsa).

DEXAMETHASONE MEDSURGE dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dexamethasone medsurge dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 ml solution for injection ampoule

medsurge pharma pty ltd - dexamethasone sodium phosphate, quantity: 8.75 mg (equivalent: dexamethasone phosphate, qty 8 mg) - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sodium citrate dihydrate; creatinine - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy.,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available.,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support: dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock: dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

DEXAMETHASONE MEDSURGE dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dexamethasone medsurge dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection, solution - excipient ingredients: sodium citrate dihydrate; creatinine; water for injections; sodium hydroxide; disodium edetate - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy.,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available.,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support: dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock: dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

ESMOLOL HYDROCHLORIDE MEDSURGE esmolol hydrochloride 100 mg/10 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

esmolol hydrochloride medsurge esmolol hydrochloride 100 mg/10 ml solution for injection vial

medsurge pharma pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - esmolol hydrochloride medsurge is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride medsurge is also indicated in non-compensatory sinus tachycardia where, in the physician?s judgement, the rapid heart rate requires specific intervention. esmolol hydrochloride medsurge is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

MEDSURGE ALFENTANIL alfentanil (as hydrochloride) 5 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge alfentanil alfentanil (as hydrochloride) 5 mg/10 ml solution for injection ampoule

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 5.44 mg (equivalent: alfentanil, qty 5 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

MEDSURGE ALFENTANIL alfentanil (as hydrochloride) 1 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge alfentanil alfentanil (as hydrochloride) 1 mg/2 ml solution for injection ampoule

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 1.09 mg (equivalent: alfentanil, qty 1 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

MEDSURGE HYDROMORPHONE HP 10 mg/1 mL hydromorphone hydrochloride 10 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone hp 10 mg/1 ml hydromorphone hydrochloride 10 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium citrate dihydrate; sodium chloride; citric acid; sodium hydroxide - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE 2 mg/1 mL hydromorphone hydrochloride 2 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone 2 mg/1 ml hydromorphone hydrochloride 2 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE XHP 50 mg/1 mL hydromorphone hydrochloride 50 mg/1 mL concentrated injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone xhp 50 mg/1 ml hydromorphone hydrochloride 50 mg/1 ml concentrated injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: citric acid; sodium chloride; sodium citrate dihydrate; water for injections; hydrochloric acid; sodium hydroxide - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE HP 20 mg/1 mL hydromorphone hydrochloride 20 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone hp 20 mg/1 ml hydromorphone hydrochloride 20 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.